^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Cancer

    Related cancers:
    13h
    Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors (clinicaltrials.gov)
    P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CLDN18 (Claudin 18) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • KRAS mutation • MSI-H/dMMR • HER-2 overexpression • BRAF mutation • HER-2 mutation • IDH1 mutation • CLDN18.2 expression • FGFR2 mutation • FGFR2 fusion • IDH mutation + NTRK fusion • NTRK fusion
    15h
    Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal Metastasis From Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Northwell Health | Not yet recruiting --> Recruiting
    Enrollment open
    |
    albumin-bound paclitaxel
    22h
    the HOPE trial: Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Mektovi (binimetinib) • hydroxychloroquine
    22h
    Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New trial
    24h
    LiMeT: Advanced Therapies for Liver Metastases (clinicaltrials.gov)
    P=N/A, N=625, Recruiting, IRCCS San Raffaele | N=475 --> 625 | Trial completion date: Jun 2026 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date • Tumor mutational burden
    24h
    POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric (clinicaltrials.gov)
    P=N/A, N=9, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting --> Active, not recruiting | N=72 --> 9
    Enrollment closed • Enrollment change
    1d
    Molecular Mechanism of Caspase-8-Dependent Interleukin-18 Activation in Pancreatic Cancer Cells Induced by 5-Fluorouracil and Nutrient Starvation. (PubMed, Genes Cells)
    Interleukin-18 (IL-18) is a pro-inflammatory cytokine, and higher IL-18 expression in pancreatic tumors is associated with poor prognosis. On the other hand, the release of active IL-18 was not observed with gemcitabine. These findings suggest that a low-nutrient tumor microenvironment and 5-FU therapy can promote caspase-8-dependent pyroptotic cell death with IL-18 activation, potentially contributing to chronic inflammation in pancreatic tumors.
    Journal
    |
    CASP8 (Caspase 8) • IL18 (Interleukin 18) • CASP1 (Caspase 1)
    |
    gemcitabine • 5-fluorouracil
    1d
    Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring. (PubMed, Front Immunol)
    Future directions include multicenter prospective trials to validate multimodal models, standardize detection methods, and increase interdisciplinary collaboration. By integrating genomic, epigenetic, metabolic, and microbiome data, these models can better capture the complexity of PDAC, thereby improving patient outcomes through precision immunotherapy.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • CA 19-9 (Cancer antigen 19-9)
    1d
    A rare case of clear cell sarcoma-like/malignant gastrointestinal neuroectodermal tumor in the pancreas: case report and literature review. (PubMed, Front Med (Lausanne))
    We present the primary M-GNET in the pancreas, confirmed by molecular fluorescence in situ hybridization (FISH) detection of EWSR1-ATF1 gene fusion. This article will summarize the clinicopathological features and differential diagnosis and review the relevant literature.
    Journal
    |
    EWSR1 (EWS RNA Binding Protein 1) • ATF1 (Activating Transcription Factor 1) • CREB1 (CAMP Responsive Element Binding Protein 1)
    1d
    Acute Pancreatitis as the Initial Presentation of Metastatic Breast Cancer Due to Malignant Hypercalcemia: A Case Report. (PubMed, Cureus)
    Despite intensive treatment with intravenous hydration and zoledronic acid, neurological deterioration occurred; hence, after 25 days of hospitalization, the patient was discharged for home-based palliative care at the family's request. This case highlights the importance of considering metastatic malignancies, particularly breast cancer, in patients with pancreatitis of unclear etiology and severe hypercalcemia.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    zoledronic acid
    1d
    Myosin Regulatory Light Chain Silencing: Function, Mechanisms, and Therapeutic Implications in Pancreatic Cancer. (PubMed, Acta Sci Microbiol)
    These results imply that the MRCL3 pathway is mediated through AP-1 transcriptional factors. Given the lack of promising pancreatic cancer drugs, this study sheds several insights on possible targets that can lead to the treatment of this disease.
    Journal
    |
    FOS (Fos Proto-Oncogene AP-1 Transcription Factor Subunit 2) • JUN (Jun proto-oncogene)
    1d
    Recurrent pancreatic acinar cell carcinoma following a 7-year disease-free interval: A case report and literature review. (PubMed, Int J Surg Case Rep)
    Due to its rarity, PACC remains a diagnostic challenge. It has a better prognosis than PDAC; radical resection is recommended.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)